Y0000193
Carteolol for system suitability
European Pharmacopoeia (EP) Reference Standard
Synonym(s):
Carteolol monohydrochloride
Sign Into View Organizational & Contract Pricing
All Photos(1)
About This Item
Empirical Formula (Hill Notation):
C16H24N2O3 · HCl
CAS Number:
Molecular Weight:
328.83
UNSPSC Code:
41116107
NACRES:
NA.24
Recommended Products
grade
pharmaceutical primary standard
API family
carteolol
manufacturer/tradename
EDQM
application(s)
pharmaceutical (small molecule)
format
neat
storage temp.
2-8°C
InChI
1S/C16H24N2O3.ClH/c1-16(2,3)17-9-11(19)10-21-14-6-4-5-13-12(14)7-8-15(20)18-13;/h4-6,11,17,19H,7-10H2,1-3H3,(H,18,20);1H
InChI key
FYBXRCFPOTXTJF-UHFFFAOYSA-N
Looking for similar products? Visit Product Comparison Guide
General description
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.
Application
Carteolol for system suitability EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.
Packaging
The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.
Other Notes
Sales restrictions may apply.
Choose from one of the most recent versions:
Certificates of Analysis (COA)
Lot/Batch Number
Sorry, we don't have COAs for this product available online at this time.
If you need assistance, please contact Customer Support.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Kenji Nakamoto et al.
Japanese journal of ophthalmology, 54(2), 140-143 (2010-04-20)
To evaluate the effects of carteolol hydrochloride (carteolol) on 24-h variations in intraocular pressure (IOP) in patients with normal-tension glaucoma (NTG). Twelve patients with NTG were treated with carteolol 2% solution for >or=8 weeks; their pretreatment 24-h IOP variations, blood
O Ravet
Bulletin de la Societe belge d'ophtalmologie, (304)(304), 145-149 (2007-08-28)
Most ocular solutions enter the eye through the corneal epithelial barrier. In order to pass through this barrier, these hydrosoluble drugs require to be associated with a detergent agent to increase topical efficiency. Although these agents have a preservative action
Mechanism of carteolol-induced cytosolic Ca2+ mobilization in cultured vascular smooth muscle cells.
Kwou-Yeung Wu et al.
Vascular pharmacology, 53(3-4), 88-93 (2010-04-27)
An increase in cytosolic calcium concentration triggers intracellular signal transduction in vascular cells, which then regulates the vascular contraction. In the present study, the regulatory mechanism of carteolol on the intracellular free Ca(2+) ([Ca(2+)](i)) mobilization was investigated in cultured A7r5
Susumu Ishida et al.
Nippon Ganka Gakkai zasshi, 115(4), 355-361 (2011-05-24)
To investigate the effects of carteolol hydrochloride on choroidal neovascularization (CNV). Laser photocoagulation was performed to induce CNV in C 57 BL/6 mice. The response of CNV was assessed by fluorescein isothiocyanate-isolectin B 4 staining. The expression of intercellular adhesion
Kenji Kawai et al.
Nippon Ganka Gakkai zasshi, 114(8), 669-677 (2010-09-02)
We investigated both human and murine peripheral blood mononuclear cells to find which of the anti-glaucoma drugs used to lower intraocular pressure drug also suppresses inflammation. Peripheral blood mononuclear cells (PBMCs) prepared from healthy men and from BALB/c mice were
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service